Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Brand Name :
hemgenix
Synonyms :
etranacogene dezaparvovec
Class :
Anti hemophilic agent,Gene therapy
Dosage Forms & StrengthsÂ
InjectionÂ
1*103 genome copies/ml IntravenousÂ
Available as 10ml vialsÂ
2*1000 genome copies/kg intravenous(2ml/kg)-single dose
Frequency defined:Â Â
>10%Â
AST increasedÂ
Infusion-related reactionsÂ
Flu-like symptomsÂ
ALT increasedÂ
Blood creatinine kinase increasedÂ
HeadacheÂ
FatigueÂ
1-10%Â
HypersensitivityÂ
NauseaÂ
Pregnancy consideration: Not recommended for use in femalesÂ
Lactation: Not recommended for use in femalesÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: etranacogene dezaparvovecÂ
Pronounced: –Â
Why do we use etranacogene dezaparvovec?Â
It is used for the treatment of congenital factor IX deficiency (hemophilia B)Â